GlassScriptPhysician profile
Sandeep Mehta
NPI 1780939967
$5,024.59
in general payments reported to CMS, 2019-2025
24 companies · $17.94 in 2025
The $17.94 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,516 · 2020: $286 · 2021: $1,020 · 2022: $640 · 2023: $446 · 2024: $98.79 · 2025: $17.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $562.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $2,126.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $832.95 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $315.90 | 2019-2023 | Evkeeza |
| Boston Scientific Corporation | $210.52 | 2019-2023 | |
| Esperion Therapeutics, INC. | $163.54 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $153.93 | 2023-2024 | Lifevest |
| Abbott Laboratories | $147.80 | 2023 | Mitraclip |
| Penumbra, INC. | $140.06 | 2021 | |
| Amgen INC. | $127.90 | 2020-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $106.43 | 2021-2023 | Farxiga, Andexxa |
| Pfizer INC. | $99.50 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $93.67 | 2021-2023 | Arcalyst |
| Amarin Pharma, INC. | $89.84 | 2019-2022 | |
| Irhythm Technologies, INC. | $82.50 | 2021-2023 | Zio Xt Patch |
| Janssen Pharmaceuticals, INC | $79.72 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.96 | 2021-2022 | |
| Medtronic Vascular, INC. | $40.45 | 2019 | |
| Lantheus Medical Imaging, INC. | $38.76 | 2019-2023 | Definity |
| Impulse Dynamics (USA) INC. | $28.73 | 2022 | |
| Merck Sharp & Dohme LLC | $24.58 | 2022 | |
| Novo Nordisk INC | $20.48 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.36 | 2022 | |
| Portola Pharmaceuticals, LLC | $19.23 | 2019 | |
| Bridgebio Pharma, INC. | $17.94 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.